Page 87 - e-CPG-SLE-8_5_24
P. 87

Management of Systemic Lupus Erythematosus

                                                          Appendix 8

                 FREQUENCY OF MONITORING PATIENTS WITH SLE
                                       Patients with
                                       active disease  Patients with stable/
                               At first             low disease activity
            Assessments              should be reviewed
                                visit               should be reviewed
                                       at least every  every 6 - 12 months
                                       1 - 3 months
            Clinical
            History                                      
            Vital signs (blood                           
            pressure, heart rate,
            weight)
            Clinical examination                         
            Drug review                                  
            Blood tests
            Full blood count                             
            Renal profile                                
            Liver function test                          
            CRP                            a              a
            ESR                                          
            Bone profile (calcium,   a     a              a
            phosphate, ALP)
            Vitamin D3           a        -                a
            Immunology/serology
            ANA                           -               -
            Anti-dsDNA                     a              a
            C3/C4 levels                                  a
            aPL (LA, aCL, aβ2GPI)          a              a,p
            ENA (anti-Ro/La, anti-RNP,     a              a,p
            anti-Sm antibodies)
            Immunoglobulin A, G, M   a     a              a
            Direct Coombs’ test            a              a
            Urine
            UFEME                                        
            Urine random protein:
            creatinine ratio OR    a       a              a
            24-hour urine protein
            Other investigation
            Culture              a         a              a
            Biopsy (e.g. skin, kidney)   a   a            a
            Neurophysiology (e.g.    a     a              a
            nerve conduction study,
            EMG)                 a         a              a
            ECG                  a         a              a
            Echocardiogram       a         a              a
            Imaging
            Chest X-ray          a         a              a
            Others (US, CT, MRI)   a       a              a

                                      70








                                       Patients with
                                       active disease  Patients with stable/
                               At first             low disease activity
            Assessments              should be reviewed
                                visit               should be reviewed
                                       at least every  every 6 - 12 months
                                       1 - 3 months
            Modifiable cardiovascular
            risk factors
            Hypertension                                 
            Dyslipidaemia                  a              a
            Diabetes mellitus                            
            High BMI                                     
            Smoking/vaping                               
   82   83   84   85   86   87   88   89   90   91   92